<DOC>
	<DOCNO>NCT00322153</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerability , efficacy memantine compare placebo outpatient diagnose moderate-to-severe dementia Alzheimer 's type concurrent acetylcholinesterase inhibitor ( AChEI ) .</brief_summary>
	<brief_title>A Study Safety Efficacy Memantine Moderate Severe Alzheimer 's Disease</brief_title>
	<detailed_description>Memantine therapeutic agent represent unique class Alzheimer 's disease ( AD ) treatment option . A daily ( QD ) dose regimen AD population would simplify administration caregiver . The purpose study evaluate safety efficacy modify release memantine take daily outpatient moderate-to-severe AD concurrent AChEI .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Ambulatory patient age &gt; /= 50 year Diagnostic evidence probable Alzheimer 's disease consistent criterion National Institute Neurological Communicative Disorders StrokeAlzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) Confirmatory magnetic resonance imaging ( MRI ) compute tomographic ( CT ) scan within prior 12 month . MiniMental State Examination ( MMSE ) score &gt; /= 3 &lt; /= 14 Screening ( Visit 1 ) Baseline ( Visit 2 ) Ongoing daily acetylcholinesterase inhibitor ( AChEI ) therapy stable dose least 3 month prior Screening ( Visit 1 ) . It prefer patient continue receive AChEI therapy duration study . Patients modify Hachinski Ischemia Score great 4 Screening . Patients take memantine within one month Screening ( Visit 1 ) Patients know hypersensitivity memantine , neramexane , rimantadine , amantadine . Patients whose AChEI therapy likely interrupted discontinue course study . Patients receive therapy one AChEI . Patients compute tomography ( CT ) magnetic resonance imaging ( MRI ) evidence hydrocephalus , stroke , spaceoccupying lesion , cerebral infection , clinically significant central nervous system disease Alzheimer 's disease . Patients DSMIV Axis I disorder Alzheimer 's disease , include amnestic disorder , schizophrenia schizoaffective disorder , bipolar disorder , current major depressive episode , psychosis , panic , posttraumatic stress disorder . Patients , clinician 's judgement , likely place nursing home within next 6 month . Patients evidence neurological disorder include , limit , stroke , Parkinson 's disease , seizure disorder , head injury loss consciousness within prior 5 year Patients dementia complicate organic disease Patients dementia complicate presence predominant delusion</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>memantine</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>moderate severe Alzheimer 's disease</keyword>
</DOC>